Jubilant

Jubilant Therapeutics Strengthens Board of Directors with Addition of Leila Alland, M.D. and Announces Appointment of Jeremy Barton, M.D., as Strategic Advisor and Interim CMO

Retrieved on: 
Monday, August 16, 2021
Memorial Sloan Kettering Cancer Center, Biogen, Memorial, Degenerative disease, UCL Medical School, PRMT5, Interim, Faculty of Pharmaceutical Medicine, Company, LinkedIn, Pfizer, Faculty, Teaching hospital, Therapy, Twitter, Schering-Plough, Pharmaceutical medicine, Albert Einstein College of Medicine, AstraZeneca, Bristol Myers Squibb, Novartis, United Kingdom, Research, Board, Patient, Royal College of Physicians and Surgeons of Canada, Assistant, Algorithm, Board of directors, University of Oxford, Cancer, Internal medicine, Self-signed certificate, Bedminster, Jubilant, Royal college, Pediatrics, Affimer, Oncology, Pharmaceutical industry, Medical imaging

to its Board of Directors, and Jeremy Barton, M.D.

Key Points: 
  • to its Board of Directors, and Jeremy Barton, M.D.
  • Previously, she served as Chief Medical Officer at Affimed and Tarveda Therapeutics and held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough.
  • Previously, Dr. Barton served as Chief Medical Officer at Biogen Idec, eFFECTOR Therapeutics, and Mirati Therapeutics.
  • Jubilant Therapeutics is headquartered in Bedminster NJ and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Strengthens Board of Directors with Addition of Leila Alland, M.D. and Announces Appointment of Jeremy Barton, M.D., as Strategic Advisor and Interim CMO

Retrieved on: 
Monday, August 16, 2021
Memorial Sloan Kettering Cancer Center, Multimedia, Biogen, Memorial, Degenerative disease, UCL Medical School, PRMT5, Interim, Faculty of Pharmaceutical Medicine, Company, LinkedIn, Pfizer, Faculty, Teaching hospital, Therapy, Twitter, Schering-Plough, Pharmaceutical medicine, Albert Einstein College of Medicine, AstraZeneca, Bristol Myers Squibb, Novartis, United Kingdom, Research, Board, View, Patient, Royal College of Physicians and Surgeons of Canada, Assistant, Algorithm, Board of directors, University of Oxford, Cancer, Internal medicine, Self-signed certificate, Bedminster, Jubilant, Royal college, Pediatrics, Affimer, Oncology, Pharmaceutical industry, Medical imaging

to its Board of Directors, and Jeremy Barton, M.D.

Key Points: 
  • to its Board of Directors, and Jeremy Barton, M.D.
  • Previously, she served as Chief Medical Officer at Affimed and Tarveda Therapeutics and held leadership positions at AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough.
  • Previously, Dr. Barton served as Chief Medical Officer at Biogen Idec, eFFECTOR Therapeutics, and Mirati Therapeutics.
  • Jubilant Therapeutics is headquartered in Bedminster NJ and guided by globally renowned key opinion leaders and scientific advisory board members.

Ocugen Provides Business Update and Second Quarter 2021 Financial Results

Retrieved on: 
Friday, August 6, 2021
Growth, Industry, Import, Health Canada, Company, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Russell, Clinical trial, Food, Diabetes, Safety, Call, Commercial, Drug, Security (finance), Vaccine, Risk, Research and development, COVID-19, Use, NASDAQ, Patient, BLA, Communication, Webcast, Delta, Development, Supply chain, ID, Biologics license application, FDA, File, U.S. FDA, SEC, Advertising, Publication, Diabetic retinopathy, Chemistry, Interim order, Bharat Biotech, Retina, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Jubilant, Senior, Fine chemical, Pharmaceutical industry, Risk management

MALVERN, Pa., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported second quarter 2021 financial results along with a general business update.

Key Points: 
  • ET
    Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continue
    The Company experienced organizational growth to reflect new business requirements in clinical development, manufacturing, and commercialization
    MALVERN, Pa., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today reported second quarter 2021 financial results along with a general business update.
  • Overall, Im very pleased with our growth and efforts to date, said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
  • Ocugens cash, cash equivalents, and restricted cash totaled $115.8million as of June30, 2021, compared to $24.2million as of December31, 2020.
  • Ocugen has scheduled a conference call and webcast for 8:30 a.m. eastern time today to discuss the financial results and recent business highlights.

H.B. Fuller Announces Strategic Partnership with Jubilant Industries

Retrieved on: 
Tuesday, June 29, 2021
Forest Products, Chemicals, Plastics, Natural Resources, Manufacturing, Jubilant, H.B. Fuller, Jubilant Agri and Consumer Products Limited, H.B. FULLER, JUBILANT AGRI AND CONSUMER PRODUCTS LIMITED

Fuller (NYSE: FUL) has announced today that it has signed a distribution agreement with Jubilant Agri and Consumer Products Limited (JACPL), a 100% subsidiary of Jubilant Industries Limited, to address the growing demand for adhesive applications in the B2B woodworking segment.

Key Points: 
  • Fuller (NYSE: FUL) has announced today that it has signed a distribution agreement with Jubilant Agri and Consumer Products Limited (JACPL), a 100% subsidiary of Jubilant Industries Limited, to address the growing demand for adhesive applications in the B2B woodworking segment.
  • Fuller and Jubilant Industries announced a strategic partnership for the Woodworking industry in India.
  • Fuller to expand our presence in the woodworking market in India," said Manu Ahuja, CEO & Managing Director, Jubilant Industries.
  • Jubilant Industries Ltd (JIL), is listed on BSE & NSE since February 2011.

Jubilant Radiopharma and Isotopia Molecular Imaging Enter into a Strategic Partnership to Further Advance the Field of Radiotherapeutics

Retrieved on: 
Tuesday, March 16, 2021
Medical imaging, Molecular imaging, Jubilant

Yardley, Pennsylvania--(Newsfile Corp. - March 16, 2021) - Isotopia Molecular Imaging Limited (Isotopia) and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, have entered into a strategic commercial partnership.

Key Points: 
  • Yardley, Pennsylvania--(Newsfile Corp. - March 16, 2021) - Isotopia Molecular Imaging Limited (Isotopia) and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, have entered into a strategic commercial partnership.
  • We are delighted that in Jubilant Radiopharma we have found an excellent partner for clinical development and commercialization.
  • Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and some of Israel's leading scientists in the field of radiopharmaceuticals.
  • Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy.

Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer

Retrieved on: 
Monday, March 8, 2021
Jubilant

BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer.

Key Points: 
  • BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer.
  • Reporting directly to the Chief Executive Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community.
  • "Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team," said Syed Kazmi, Ph.D., President and Chief Executive Officer of Jubilant Therapeutics.
  • Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer

Retrieved on: 
Monday, March 8, 2021
Jubilant

BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer.

Key Points: 
  • BEDMINSTER, N.J., March 8, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, announced today the appointment of Luca Rastelli, Ph.D. as Chief Scientific Officer.
  • Reporting directly to the Chief Executive Officer, Dr. Rastelli will lead all aspects of R&D for Jubilant Therapeutics and serve as a scientific liaison for the company to investors, partners and the medical community.
  • "Luca is a highly accomplished scientist and oncology drug developer and it is a pleasure to welcome him to the team," said Syed Kazmi, Ph.D., President and Chief Executive Officer of Jubilant Therapeutics.
  • Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Therapeutics Announces Research Collaboration with Boston Children's Hospital, Harvard Medical School, to Evaluate PAD4 Inhibitors in Autoimmune/Inflammation Disease Models

Retrieved on: 
Thursday, February 25, 2021
Agencies of the European Union, European Union, European Insurance and Occupational Pensions Authority, Insurance regulation, European System of Financial Supervision, SFDR, Jubilant, Citrulline, Government, Chemistry, Physical sciences

PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.

Key Points: 
  • PAD4 is an enzyme that converts arginine to citrulline in histones and is highly expressed in neutrophils.
  • Specific PAD4 inhibitors, that are well tolerated by animals, would be great for pre-clinical and, later, human studies.
  • Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases.
  • Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.

Jubilant Biosys and Yale University announce collaboration to accelerate multiple small molecule discovery programs

Retrieved on: 
Tuesday, February 9, 2021
Biosys, Jubilant, Yale University, New Haven, Connecticut, Connecticut, Cities in the United States

NEW HAVEN, Conn. and BENGALURU, India, Feb. 9, 2021 /PRNewswire/ -- Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.

Key Points: 
  • NEW HAVEN, Conn. and BENGALURU, India, Feb. 9, 2021 /PRNewswire/ -- Today, Jubilant Biosys and Yale University have announced a research collaboration for multiple small molecule research programs.
  • Under the scope of this partnership, Jubilant Biosys will provide research services to investigators at Yale University working on novel therapeutic targets.
  • Commenting on this collaboration, Marcel Velterop, President Jubilant Biosys said "Yale is one of the top-ranked academic institutions in the US and we at Jubilant Biosys are delighted to be able to support scientific endeavours of Investigators at Yale to pursue novel target ideas for unmet medical conditions.
  • Jubilant Biosys, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has a presence in Bengaluru and Noida in India.

Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors

Retrieved on: 
Friday, February 5, 2021
Jubilant

BEDMINSTER, N.J., Feb. 5, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced the addition of Robert Glassman, M.D., to the company's Board of Directors.

Key Points: 
  • BEDMINSTER, N.J., Feb. 5, 2021 /PRNewswire/ -- Jubilant Therapeutics Inc. , a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced the addition of Robert Glassman, M.D., to the company's Board of Directors.
  • "Rob's experience and insights will bring new dimension to the company as we chalk our growth strategy and we warmly welcome him to our board," said Hari Bhartia, Chairman, Jubilant Therapeutics.
  • "I am honored to join the board of Jubilant Therapeutics and contribute to the important work the company is doing in the areas of genetically-defined cancers and autoimmune disorders," said Dr. Glassman.
  • Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.